Dedrone Momentum Adds to Axon's Growth but Valuation Stays Elevated

What happened

Axon's Q2 2026 results showed continued strength in the Dedrone counter-UAS platform, with revenues exceeding $100 million, driven by C2 upgrades and strategic partnerships. This builds on Axon's already robust growth algorithm—FY2025 revenue grew 33.5% to $2.78 billion, with future contracted bookings up 43% to $14.4 billion—but does not resolve the tariff-driven margin compression seen in FY2025. The company's GAAP operating loss of $62.1 million and adjusted gross margin decline to 62.6% highlight that rapid revenue expansion is not yet translating into operating leverage. While the Dedrone segment adds a new high-growth vertical, its contribution is still small relative to the overall business, and the stock's valuation (P/E ~319x, EV/EBITDA ~207x) leaves little room for execution missteps. Investors should view this news as a confirmation of demand rather than a thesis-changer, as the core risks—margin stabilization, NRR sustainability, and SBC dilution—remain unresolved.

Implication

Maintain a WAIT rating: the stock's risk/reward is unfavorable above $620, with an attractive entry near $440, based on the existing scenario framework. Monitor next quarter's NRR and gross margin trends closely—if NRR holds at or above 120% and adjusted gross margin stabilizes, the bull case strengthens. The Dedrone revenue milestone suggests successful execution in the counter-UAS market, potentially adding a new addressable market for Axon beyond public safety. However, the company's high SBC ($590–$620 million guided for FY2026) and ongoing GAAP losses mean per-share value creation is still unclear. Until management demonstrates consistent operating leverage and margin expansion, treat any rally driven by product-specific news as an opportunity to trim rather than accumulate.

Thesis delta

The overall investment thesis remains unchanged: AXON is a high-growth platform with exceptional demand visibility but lacks margin of safety at current prices. The Dedrone strength adds another layer of growth optionality, but it does not alter the key watch items (NRR, gross margin, SBC). No shift in rating or conviction at this time.